Dr. Botta currently sees GI oncology patients within the UCSD Moores Cancer Center, an NCCN designated comprehensive cancer center. He eagerly tailors individual treatment plans for patients based upon their specific GI cancer. Further, he readily applies cutting edge molecular profiling, genomics, and Artificial Intelligence to their case.
Cend Therapeutics is a start-up company translating peptide technology into early phase patient-centered clinical trials. Dr. Botta assisted in the development, initiation, and ongoing analysis of the Phase I trial of CEND-1 in metastatic pancreatic cancer (NCT03517176). Drs. Botta and Lowy (UCSD) along with SWOG are developing Phase II trials in the US at this time.
The Scripps Research Translational Institute (SRTI) is a member organization of Scripps Research funded by an NIH Clinical and Translational Science Award (CTSA). Dr. Botta retains an adjunct faculty appointment in Molecular Medicine at Scripps Research and has ongoing collaborations within the institute.
TumorGen MDx is a start-up company aimed at therapeutic targeting of cancer stem cells. Dr. Botta is a member of the scientific advisory board.
The Botta Laboratory previously collaborated with Erkki Ruoslahti, MD/PhD at Sanford Burnham Prebys Medical Discovery Institute (SBP). Dr. Ruoslahti is a pioneer in tumor extracellular matrix and drug targeting, a member of the National Academy of Sciences, and a Nobel-level researcher.
Copyright © 2018 Gregory Botta, MD/PhD - All Rights Reserved.
Powered by Website Builder